Literature DB >> 9635841

Mutation analysis of the c-mos proto-oncogene in human ovarian teratomas.

K A de Foy1, S A Gayther, W H Colledge, S Crockett, I V Scott, M J Evans, B A Ponder.   

Abstract

Female transgenic mice lacking a functional c-mos proto-oncogene develop ovarian teratomas, indicating that c-mos may behave as a tumour-suppressor gene for this type of tumour. We have analysed the entire coding region of the c-MOS gene in a series of human ovarian teratomas to determine whether there are any cancer-causing alterations. DNA from twenty teratomas was analysed by single-strand conformational analysis (SSCA) and heteroduplex analysis (HA) to screen for somatic and germline mutations. In nine of these tumours the entire gene was also sequenced. A previously reported polymorphism and a single new sequence variant were identified, neither of which we would predict to be disease-causing alterations. These results suggest that mutations in the coding region of the c-MOS gene do not play a significant role in the genesis of human ovarian teratomas.

Entities:  

Mesh:

Year:  1998        PMID: 9635841      PMCID: PMC2150066          DOI: 10.1038/bjc.1998.269

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

1.  A virus-induced rhabdomyosarcoma of mice.

Authors:  J B Moloney
Journal:  Natl Cancer Inst Monogr       Date:  1966-09

2.  The development of teratomas from parthenogenetically activated ovarian mouse eggs.

Authors:  L C Stevens; D S Varnum
Journal:  Dev Biol       Date:  1974-04       Impact factor: 3.582

3.  Genetics and biology of human ovarian teratomas. I. Cytogenetic analysis and mechanism of origin.

Authors:  U Surti; L Hoffner; A Chakravarti; R E Ferrell
Journal:  Am J Hum Genet       Date:  1990-10       Impact factor: 11.025

4.  Activation of the transforming potential of a normal cell sequence: a molecular model for oncogenesis.

Authors:  D G Blair; M Oskarsson; T G Wood; W L McClements; P J Fischinger; G G Vande Woude
Journal:  Science       Date:  1981-05-22       Impact factor: 47.728

5.  The c-mos proto-oncogene product is a cytostatic factor responsible for meiotic arrest in vertebrate eggs.

Authors:  N Sagata; N Watanabe; G F Vande Woude; Y Ikawa
Journal:  Nature       Date:  1989-11-30       Impact factor: 49.962

6.  Human DNA sequence homologous to the transforming gene (mos) of Moloney murine sarcoma virus.

Authors:  R Watson; M Oskarsson; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

7.  Abnormal expression of the MOS proto-oncogene in human thyroid medullary carcinoma.

Authors:  M H Parkar; J M Seid; B M Stringer; S Ingemansson; N Woodhouse; M H Goyns
Journal:  Cancer Lett       Date:  1988-12-15       Impact factor: 8.679

8.  Function of c-mos proto-oncogene product in meiotic maturation in Xenopus oocytes.

Authors:  N Sagata; M Oskarsson; T Copeland; J Brumbaugh; G F Vande Woude
Journal:  Nature       Date:  1988-10-06       Impact factor: 49.962

9.  Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.

Authors:  C Eng; K A Foster; C S Healey; C Houghton; S A Gayther; L M Mulligan; B A Ponder
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

10.  Degradation of the proto-oncogene product p39mos is not necessary for cyclin proteolysis and exit from meiotic metaphase: requirement for a Ca(2+)-calmodulin dependent event.

Authors:  T Lorca; S Galas; D Fesquet; A Devault; J C Cavadore; M Dorée
Journal:  EMBO J       Date:  1991-08       Impact factor: 11.598

View more
  2 in total

1.  Role of the inositol polyphosphate-4-phosphatase type II Inpp4b in the generation of ovarian teratomas.

Authors:  Ashwini Balakrishnan; J Richard Chaillet
Journal:  Dev Biol       Date:  2012-10-16       Impact factor: 3.582

Review 2.  Oocyte-specific genes: role in fertility and infertility.

Authors:  B Meczekalski
Journal:  J Endocrinol Invest       Date:  2009-05       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.